Advertisement
YOU ARE HERE: LAT HomeCollectionsEdwards Lifesciences Corp
IN THE NEWS

Edwards Lifesciences Corp

BUSINESS
July 28, 2004 | From Reuters
Cardiovascular device maker Edwards Lifesciences Corp. said Tuesday that its second-quarter profit rose 21%, spurred by higher sales of its heart valves. The Irvine-based company said net income rose to $25.5 million, or 41 cents a share, from $21.1 million, or 34 cents, in the same quarter a year ago. Excluding charges in the 2003 and 2004 quarters, Edwards posted earnings of $26.5 million, or 43 cents a share, in the latest quarter, compared with $23.9 million, or 39 cents, a year earlier.
Advertisement
BUSINESS
April 22, 2000 | (Leslie Earnest)
Edwards Lifesciences Corp. said Friday it has voluntarily suspended sales and clinical trials of a product that is designed to treat a weakness in the wall of an abdominal artery. The Irvine company said it took the action after discovering that a wire within the Lifepath AAA Endovascular Graft System fractured in two patients.
BUSINESS
November 1, 2000 | Marc Ballon
Edwards Lifesciences Corp.'s stock was hammered after the company said it is lowering its profit estimates for the fourth quarter and 2001 because of a weak euro and sluggish sales in several product lines. Shares of the Irvine company, which makes products that treat cardiovascular disease, plummeted more than 41%, the fifth biggest percentage loss in U.S. markets for the day. The stock closed at $13.44, down $9.50 a share, on the New York Stock Exchange.
BUSINESS
April 22, 2000 | From Bloomberg News
Edwards Lifesciences Corp., the largest maker of replacement heart valves, said Friday it has halted use of its surgical patches for protecting dangerously weakened aortas after spotting small cracks in the patches. Routine X-rays of two patients in a trial of the Lifepath AAA Endovascular Graft System revealed the cracks. Neither patient had medical problems as a result of the damaged products.
BUSINESS
July 19, 2000 | From Bloomberg News
Edwards Lifesciences Corp., the No. 1 maker of artificial heart valves, agreed on Tuesday to sell most of its unprofitable Bentley line to Germany's Jostra for about $30 million and said it plans to take charges against earnings related to the sale and severance costs for 60 employees at its Irvine headquarters and in Puerto Rico. Edwards, which was spun off by Baxter International Inc.
BUSINESS
April 1, 2000 | From Reuters
Shares of Edwards Lifesciences Corp., an Irvine developer of cardiovascular products, are scheduled to begin trading officially Monday amid a bullish earnings outlook. The new company, which is being shed by Baxter International Inc. in Deerfield, Ill., will compete against Boston Scientific Corp., Guidant Corp. and Medtronic Inc. in providing products to treat cardiovascular disorders, a market Edwards estimates at $100 billion a year.
Los Angeles Times Articles
|